BR Biopharma’s (BRBI) “Neutral” Rating Reiterated at Citigroup

BR Biopharma (NASDAQ:BRBI)‘s stock had its “neutral” rating reiterated by investment analysts at Citigroup in a report issued on Tuesday, Benzinga reports.

Separately, Weiss Ratings raised shares of BR Biopharma from a “sell (d-)” rating to a “sell (d)” rating in a report on Friday, October 2nd. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Reduce”.

BR Biopharma Stock Down 7.8%

BRBI stock traded down $0.77 during midday trading on Tuesday, hitting $9.07. The company’s stock had a trading volume of 11,343 shares, compared to its average volume of 3,461. BR Biopharma has a 12 month low of $9.08 and a 12 month high of $16.61. The firm has a market capitalization of $107.12 million and a price-to-earnings ratio of 113.38. The company has a 50 day moving average of $11.85 and a two-hundred day moving average of $12.85.

BR Biopharma (NASDAQ:BRBI) last announced its quarterly earnings data on Tuesday, June 30th. The company reported $0.09 earnings per share (EPS) for the quarter. The company had revenue of $25.13 million for the quarter.

Hedge Funds Weigh In On BR Biopharma

A hedge fund recently bought a new stake in BR Biopharma stock. Acuitas Investments LLC purchased a new stake in shares of BR Biopharma, Inc. (NASDAQ:BRBI) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 3,000 shares of the company’s stock, valued at approximately $45,000. BR Biopharma makes up 3.2% of Acuitas Investments LLC’s holdings, making the stock its 7th biggest holding.

About BR Biopharma

BRBI BR Partners SA, through its subsidiaries, operates as an investment bank which specializes in providing financial services for entrepreneurs and families principally in Brazil. It offers financial advisory services for mergers and acquisitions, capital markets, board services, shareholders, special situations and restructuring, pre-IPO, and privatization; and wealth management services. BRBI BR Partners SA is based in S?o Paulo, Brazil.